These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort. Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583 [TBL] [Abstract][Full Text] [Related]
44. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing. O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR Front Immunol; 2023; 14():1055429. PubMed ID: 36845123 [TBL] [Abstract][Full Text] [Related]
45. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.]. Casas Fischer R Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347 [TBL] [Abstract][Full Text] [Related]
46. 9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients. Stumpf J; Anders L; Siepmann T; Schwöbel J; Karger C; Lindner T; Faulhaber-Walter R; Langer T; Escher K; Anding-Rost K; Seidel H; Hüther J; Pistrosch F; Martin H; Schewe J; Stehr T; Meistring F; Paliege A; Schneider D; Bast I; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Skrzypczyk S; Anft M; Klimova A; Mauer R; Roeder I; Tonn T; Babel N; Hugo C Vaccine; 2024 Jan; 42(2):120-128. PubMed ID: 38114410 [TBL] [Abstract][Full Text] [Related]
47. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination. Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800 [TBL] [Abstract][Full Text] [Related]
48. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents. Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040 [TBL] [Abstract][Full Text] [Related]
49. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375 [TBL] [Abstract][Full Text] [Related]
50. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children. Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243 [TBL] [Abstract][Full Text] [Related]
51. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
52. Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations. Titova E; Kan VW; Lozy T; Ip A; Shier K; Prakash VP; Starolis M; Ansari S; Goldgirsh K; Kim S; Pelliccia MC; Mccutchen A; Megalla M; Gunning TS; Kaufman HW; Meyer WA; Perlin DS Microbiol Spectr; 2024 Mar; 12(3):e0205023. PubMed ID: 38353557 [TBL] [Abstract][Full Text] [Related]
53. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. Seidel A; Zanoni M; Groß R; Krnavek D; Erdemci-Evin S; von Maltitz P; Albers DPJ; Conzelmann C; Liu S; Weil T; Mayer B; Hoffmann M; Pöhlmann S; Beil A; Kroschel J; Kirchhoff F; Münch J; Müller JA Front Immunol; 2022; 13():882918. PubMed ID: 35958601 [TBL] [Abstract][Full Text] [Related]
55. Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses' Vaccinated Solid Organ Transplant Recipients. Busà R; Russelli G; Miele M; Sorrentino MC; Di Bella M; Timoneri F; Di Mento G; Mularoni A; Vitulo P; Conaldi PG; Bulati M Viruses; 2022 Oct; 14(10):. PubMed ID: 36298854 [TBL] [Abstract][Full Text] [Related]
56. Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination. Zedan HT; Smatti MK; Thomas S; Nasrallah GK; Afifi NM; Hssain AA; Abu Raddad LJ; Coyle PV; Grivel JC; Almaslamani MA; Althani AA; Yassine HM JAMA Netw Open; 2023 Jun; 6(6):e2319222. PubMed ID: 37389876 [TBL] [Abstract][Full Text] [Related]
57. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM Elife; 2022 Jan; 11():. PubMed ID: 35072628 [TBL] [Abstract][Full Text] [Related]
58. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection. Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY Front Immunol; 2023; 14():1131229. PubMed ID: 36960070 [TBL] [Abstract][Full Text] [Related]
59. Immune Response 5-7 Months after Vaccination against SARS-CoV-2 in Elderly Nursing Home Residents in the Czech Republic: Comparison of Three Vaccines. Martínek J; Tomášková H; Janošek J; Zelená H; Kloudová A; Mrázek J; Ježo E; Král V; Pohořská J; Šturcová H; Maďar R Viruses; 2022 May; 14(5):. PubMed ID: 35632827 [TBL] [Abstract][Full Text] [Related]
60. Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. Vogrig M; Berger AE; Bourlet T; Waeckel L; Haccourt A; Chanavat A; Hupin D; Roche F; Botelho-Nevers E; Pozzetto B; Paul S J Clin Immunol; 2023 Jan; 43(1):31-45. PubMed ID: 36006568 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]